A clinical trial conducted at UNC Lineberger Comprehensive Cancer Center and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center found that…
Home »
New prediction model can identify NSCLC patients who are not likely to respond to immunotherapy
Immunotherapy agents that inhibit the molecules PD1, PD-L1 or CTLA-4 have become widely used in clinical practice to treat non-small…
Newly identified protein could become a target for future cancer treatments
Researchers at the Francis Crick Institute have identified a protein that helps tumours evade the immune system and, in certain…
Adverse Reactions to Immunotherapy Can Appear After a Year
Clinicians should be on the lookout for immune-related adverse reactions (irAEs) even after patients have been receiving anti–programmed cell death…
New approach to cancer immunotherapy may prevent autoimmunity
A team of researchers has found disrupting the interaction between cancer cells and certain immune cells is more effective at…
Researchers develop mutant gene-targeted immunotherapy approach to fight cancers
A novel targeted immunotherapy approach developed by researchers at the Ludwig Center, the Lustgarten Laboratory, and Bloomberg~Kimmel Institute for Cancer…
Adjuvant Nivolumab: A New Standard of Care in High-risk MIUC?
The checkpoint inhibitor nivolumab is efficacious and well tolerated when used as adjuvant therapy in patients who have undergone radical…
Insight about tumor microenvironment could boost cancer immunotherapy
A paper published today in Nature shows how chemicals in the areas surrounding tumors—known as the tumor microenvironment—subvert the immune…
Response to cancer immunotherapy may be affected by genes we carry from birth
For all their importance as a breakthrough treatment, the cancer immunotherapies known as checkpoint inhibitors still only benefit a small…
FDA Approves Libtayo (cemiplimab-rwlc) as First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma
TARRYTOWN, N.Y. and PARIS, Feb. 9, 2021 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S.…